Auxilium falls on lower guidance

Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) fell $1.25 to $17.49 on Monday after lowering full-year guidance. The company now expects $254-$271 million in revenue for the year, down from previous expectations of $259-$281 million. Auxilium attributed the change to lower expectations for Xiaflex collagenase clostridium histolyticum, which is expected to record $45-$50 million in U.S. revenue, down from $50-$60 million. The company said the number of Xiaflex procedures to treat Dupuytren's contracture performed in the second quarter was lower than previously expected. Net loss guidance is now $40-$45 million, wider than previous guidance of $31-$41 million.

Auxilium reported 2Q11 revenues of $65.9 million, up 30% from $50.5 million in 2Q10. The Street was expecting $64.9 million. Revenues for Xiaflex were $15.4 million, up from $3.1 million in 2Q10. Auxilium launched the injectable form of collagenase in the U.S. in March 2010. ...